Takeda's Zasocitinib Receives FDA Priority Review for Psoriasis

The FDA has granted Priority Review to Takeda's New Drug Application for zasocitinib (TAK-279) to treat moderate-to-severe plaque psoriasis in adults. This investigational oral TYK2 inhibitor showed rapid and durable skin clearance in Phase 3 trials. Priority Review status indicates the FDA's intent to expedite the review process for drugs that could offer significant improvements over available therapies.